Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: Accuracy of patient recall of arthritis symptom onset

Journal of Rheumatology

Volumn 31, Issue 9, 2004, Pages 1686-1692

  Sogolamjadi Begvand, ^a   Khanna, Dinesh ^a   Park, Grace S ^a   Bulpitt, Ken J ^a   Wong, Weng Kee ^a   Paulus, Harold E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Early rheumatoid arthritis; Patient recall; Symptom onset; Window of therapeutic opportunity

Indexed keywords

RHEUMATOID FACTOR;

ACCURACY; ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL; QUESTIONNAIRE; RECALL; RHEUMATOID ARTHRITIS; SELF REPORT; SYMPTOM;

ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; HUMANS; LONGITUDINAL STUDIES; MEDICAL HISTORY TAKING; MENTAL RECALL; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 4444264304     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
2. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003;48:1771-4.
3. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
4. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
5. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
6. O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001;44:2235-41.
7. Mottonen T, Hannonen P, Korpela M, et al, for the FIN-RACo Trial group. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
8. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
9. Paulus HE, Ramos B, Wong WK, et al. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity and Westergren erythrocyte sedimentation rate when used to calculate ACR 20% improvement criteria or the Disease Activity Score in early rheumatoid arthritis patients. J Rheumatol 1999;26:2324-31.
10. Wong AL, Wong WK, Harker J, et al. Patient self report tender and swollen joint counts. J Rheumatol 1999;26:2551-61.
11. Newhall-Perry K, Law NJ, Ramos B, et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol 2000;27:1156-63.
12. Paulus HE, Bulpitt KJ, Ramos B, Park G, Wong WK, for the Western Consortium of Practicing Rheumatologists. Relative contributions of the components of the American College of Rheumatology 20% definition of improvement to responder status in patients with early sero-positive rheumatoid arthritis. Arthritis Rheum 2000;43:2743-50.
13. Paulus HE, Wiesner J, Bulpitt KJ, et al. Autoantibodies in early seropositive RA, before and during disease modifying antirheumatic drug treatment. J Rheumatol 2002;29:2513-20.
14. Paulus HE, Oh MS, Sharp JT, et al. Correlation of single time-point damage scores with observed progression of radiographic damage during the first 6 years of RA. J Rheumatol 2003;30:705-13.
15. van der Heijde DM, van't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
16. van der Heijde DMFM, van't Hof MA, van Piel PLCM, van Leeuwen MA, van Rijswijk MH, van de Putte LB. A comparison of validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;52:177-81.
17. Stata Corporation. Estimate population-averaged panel-data models using GEE. In: Stata Corporation. Stata 7 Stata Reference Manual, Release 7, Volume 2 Su-Z. College Station, TX: Stata Press; 2001:325-46.
18. Barsky AJ. Forgetting, fabricating, and telescoping: The instability of the medical history. Arch Intern Med 2002;162:981-4.
19. Skowronski JJ, Thompson CP. Reconstructing the dates of personal events: Gender differences in accuracy. Appl Cogn Psychol 1990;4:371-81.
20. Bradburn NM. Temporal representation and event dating. In: Stone AA, Turkkan JS, Bachrach CA, Jobe JB, Kurtzman HS, Cain VS, editors. The science of self-report: implications for research and practice. Mahwah, NJ: Lawrence Erlbaum Associates; 2000:49-61.
21. Hannonen P, Möttönen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501-9.
22. Harrison BJ, Symmons DP, Brennan P, Barren EM, Silman AJ. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 1996;35:1096-100.
23. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
24. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
25. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
26. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
27. Fleming A, Crown JM, Corbett M. Early rheumatoid disease: I. Onset. Ann Rheum Dis 1976;35:357-60.
28. Thompson CP. Memory for unique personal events: the roommate study. Mem Cognit 1982;10:324-32.
29. Pincus T, Gibofsky A, Weinblatt ME. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum 2002;46:851-4.
30. Kim JM, Weisman MH. When does rheumatoid arthritis begin and why do we need to know. Arthritis Rheum 2000;43:473-4.
31. van der Horst-Bruinsma IE, Speyer E, Visser H, Breedveld FC, Hazes JMW. Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998;37:1084-8.
32. Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670-6.